Shares of METIS TECHBIO-P (07666) extended their recent gains, rising over 3% during the trading session. The stock has now accumulated an increase of more than 20% over the past five trading days, pushing its total market capitalization beyond HK$170 billion.

The upward momentum follows the company's recent announcement of a strategic alliance with Deerfield, a leading global health investment and innovation platform. This partnership aims to deeply integrate METIS TECHBIO-P's proprietary technologies in AI-driven protein engineering, in vivo immunotherapies, and programmable biologics with Deerfield's extensive industry expertise and capabilities in translational medicine, clinical development, healthcare innovation, and global collaboration.

As part of this alliance, Deerfield will engage in deep collaboration with METIS TECHBIO-P on the global clinical development and commercial expansion of the company's self-developed AI-enabled nano-delivery platform, NanoForge, along with its related solutions and core pipeline projects. This includes a leading T-cell engager (TCE) project discovered and advanced to the pre-clinical candidate stage by METIS TECHBIO-P's proprietary AiProtein platform.

Deerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.